Real-time PCR assay compared to nested PCR and antigenemia assays for detecting cytomegalovirus reactivation in adult T-Cell leukemia-lymphoma patients

被引:21
作者
Ikewaki, J [1 ]
Ohtsuka, E [1 ]
Kawano, R [1 ]
Ogata, M [1 ]
Kikuchi, H [1 ]
Nasu, M [1 ]
机构
[1] Oita Med Univ, Dept Infect Dis, Oita 8795593, Japan
关键词
D O I
10.1128/JCM.41.9.4382-4387.2003
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
We analyzed the efficiency of the quantitative real-time PCR assay for cytomegalovirus (CMV) reactivation in adult T-cell leukemia-lymphoma (ATL) patients and compared the results with those obtained with qualitative nested PCR and antigenemia assays. The viral load obtained by the real-time PCR assay closely paralleled the number of antigen-positive cells obtained with the antigenemia assay. Real-time PCR revealed that a large number of DNA copies could be present even in samples assessed as negative or low in antigen-positive cells (0 to 10 antigen-positive cells/50,000 cells) by antigenemia assay. CMV copy numbers did not differ between the negative and low-antigen-positive groups. When the input concentration for real-time PCR assay was 2,500 to 5,000 copies/ml, the positivity rate for the nested PCR assay was 47.3%, while the positivity rate was more than 90% at an input concentration of greater than or equal to:50,000 copies/ml. Real-time PCR is more sensitive than the antigenemia and nested PCR assays. Moreover, real-time PCR was able to detect CMV reactivation earlier than the antigenemia and nested PCR assays through the use of longitudinal analysis in four ATL patients with CMV pneumonia. In longitudinal assessments, analysis of the results suggested that a cutoff level of 5,000 copies/ml might be used to initiate treatment. Real-time PCR is more suitable for monitoring CMV reactivation in ATL patients than the antigenemia and nested PCR assays. CMV viral loads of 5,000 copies/ml are proposed as the cutoff for initiating antiviral therapy in ATL patients.
引用
收藏
页码:4382 / 4387
页数:6
相关论文
共 35 条
  • [1] Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients
    Boeckh, M
    Bowden, RA
    Gooley, T
    Myerson, D
    Corey, L
    [J]. BLOOD, 1999, 93 (05) : 1781 - 1782
  • [2] Cytomegalovirus reactivation in patients infected with HIV - The use of polymerase chain reaction in prediction and management
    Bowen, EF
    [J]. DRUGS, 1999, 57 (05) : 735 - 741
  • [3] Comparison of quantitative and qualitative PCR assays for cytomegalovirus DNA in plasma
    Caliendo, AM
    Schuurman, R
    Yen-Lieberman, B
    Spector, SA
    Andersen, J
    Manjiry, R
    Crumpacker, C
    Lurain, NS
    Erice, A
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (04) : 1334 - 1338
  • [4] Comparison between antigenemia and a quantitative-competitive polymerase chain reaction for the diagnosis of cytomegalovirus infection after heart transplantation
    Camargo, LFA
    Uip, DE
    Simpson, AAG
    Caballero, O
    Stolf, NAG
    Vilas-Boas, LS
    Pannuti, CS
    [J]. TRANSPLANTATION, 2001, 71 (03) : 412 - 417
  • [5] CYTOMEGALOVIRUS INFECTIONS IN ADULT T-CELL LEUKEMIA PATIENTS
    EIZURU, Y
    TAMURA, K
    MINAMISHIMA, Y
    OGATA, K
    TADA, S
    INOUE, S
    TAKESHITA, M
    KIKUCHI, M
    [J]. JOURNAL OF MEDICAL VIROLOGY, 1987, 23 (02) : 123 - 133
  • [6] The significance of cytomegalovirus infection over the clinical course of adult T-cell leukemia/lymphoma
    Fujiwara, H
    Eizuru, Y
    Matsumoto, T
    Kukita, T
    Imaizumi, R
    Kawada, H
    Ohtsubo, H
    Matsushita, K
    Arima, N
    Tei, C
    [J]. MICROBIOLOGY AND IMMUNOLOGY, 2001, 45 (01) : 97 - 100
  • [7] Fujiwara H, 2000, J MED VIROL, V62, P140, DOI 10.1002/1096-9071(200010)62:2&lt
  • [8] 140::AID-JMV3&gt
  • [9] 3.0.CO
  • [10] 2-X